
Global Molecular Cytogenetics Market
Global molecular cytogenetics market by product (software and service, consumable, instrument), by technology (comparative genomic hybridization, FISH, immunochemistry, karyotyping, others), by application (genetic disorder, oncology, personalized medicine, others), by end user (clinical and research laboratory, hospitals and path lab, academic research institute, pharmaceutical and biotech company, others), by region (North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America), outlook & forecast, 2022-2028
Description
The global molecular cytogenetics market is projected to rise by USD 1.9 billion by 2028, according to a new report by Gen Consulting Company. It is anticipated to expand at a CAGR of 12.3 percent during the forecast period.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global molecular cytogenetics market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the molecular cytogenetics industry.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, technology, application, end user, and region. The global market for molecular cytogenetics can be segmented by product: software and service, consumable, instrument. Globally, the consumable segment made up the largest share of the molecular cytogenetics market. Molecular cytogenetics market is further segmented by technology: comparative genomic hybridization, FISH, immunochemistry, karyotyping, others. The comparative genomic hybridization segment captured the largest share of the market in 2021. Based on application, the molecular cytogenetics market is segmented into: genetic disorder, oncology, personalized medicine, others. According to the research, the oncology segment had the largest share in the global molecular cytogenetics market. On the basis of end user, the molecular cytogenetics market also can be divided into: clinical and research laboratory, hospitals and path lab, academic research institute, pharmaceutical and biotech company, others. The clinical and research laboratory segment held the largest revenue share in 2021. Molecular cytogenetics market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America.
Market Segmentation
By product: software and service, consumable, instrument
By technology: comparative genomic hybridization, FISH, immunochemistry, karyotyping, others
By application: genetic disorder, oncology, personalized medicine, others
By end user: clinical and research laboratory, hospitals and path lab, academic research institute, pharmaceutical and biotech company, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The global molecular cytogenetics market report offers detailed information on several market vendors, including Agilent Technologies, Inc., Associated Regional and University Pathologists, Inc., Bio View Ltd., F. Hoffmann-La Roche Ltd, Illumina, Inc., Oxford Nanopore Technologies Limited, PerkinElmer Inc., Roche Holding AG, among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.
Scope of the Report
– To analyze and forecast the market size of the global molecular cytogenetics market.
– To classify and forecast the global molecular cytogenetics market based on product, technology, application, end user, region.
– To identify drivers and challenges for the global molecular cytogenetics market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global molecular cytogenetics market.
– To identify and analyze the profile of leading players operating in the global molecular cytogenetics market.
Why Choose This Report
– Gain a reliable outlook of the global molecular cytogenetics market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.
Table of Contents
TABLE OF CONTENTS
FIGURES AND TABLES
PART 1. INTRODUCTION
· Report description
· Objectives of the study
· Market segment
· Years considered for the report
· Currency
· Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
· Introduction
· Drivers
· Restraints
· Impact of COVID-19 pandemic
PART 5. MARKET BREAKDOWN BY PRODUCT
· Software and service
· Consumable
· Instrument
PART 6. MARKET BREAKDOWN BY TECHNOLOGY
· Comparative genomic hybridization
· FISH
· Immunochemistry
· Karyotyping
· Others
PART 7. MARKET BREAKDOWN BY APPLICATION
· Genetic disorder
· Oncology
· Personalized medicine
· Others
PART 8. MARKET BREAKDOWN BY END USER
· Clinical and research laboratory
· Hospitals and path lab
· Academic research institute
· Pharmaceutical and biotech company
· Others
PART 9. MARKET BREAKDOWN BY REGION
· North America
· Europe
· Asia-Pacific
· MEA (Middle East and Africa)
· Latin America
PART 10. KEY COMPANIES
· Agilent Technologies, Inc.
· Associated Regional and University Pathologists, Inc.
· Bio View Ltd.
· F. Hoffmann-La Roche Ltd
· Illumina, Inc.
· Oxford Nanopore Technologies Limited
· PerkinElmer Inc.
· Roche Holding AG
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER
Companies Mentioned
Agilent Technologies, Inc.
Associated Regional and University Pathologists, Inc.
Bio View Ltd.
F. Hoffmann-La Roche Ltd
Illumina, Inc.
Oxford Nanopore Technologies Limited
PerkinElmer Inc.
Roche Holding AG